Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Phase 3
Completed
- Conditions
- Overactive Bladder
- Interventions
- Biological: onabotulinumtoxinADrug: normal saline
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 548
- Registration Number
- NCT00910520
Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin
Phase 3
Completed
- Conditions
- Hypotrichosis
- Interventions
- Drug: Vehicle solution
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 368
- Registration Number
- NCT00907426
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
Phase 1
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Biological: Botulinum Toxin Type ADrug: Placebo (saline)
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 61
- Registration Number
- NCT00894517
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
Phase 3
Completed
- Conditions
- Atopic Conjunctivitis
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2012-11-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 176
- Registration Number
- NCT00884585
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
Phase 3
Completed
- Conditions
- Overactive Bladder
- Interventions
- Biological: Botulinum Toxin Type A 200UBiological: Botulinum Toxin Type A 300U
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Allergan
- Target Recruit Count
- 397
- Registration Number
- NCT00876447
A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms
Phase 4
Completed
- Conditions
- Anti-biotic Resistance
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 66
- Registration Number
- NCT00874887
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
Phase 4
Completed
- Conditions
- PharmacokineticsElderlyOveractive Bladder
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 12
- Registration Number
- NCT00863551
Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
Phase 4
Completed
- Conditions
- Skin Aging
- Interventions
- Biological: botulinum toxin Type A
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Allergan
- Target Recruit Count
- 45
- Registration Number
- NCT00856414
CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy
Completed
- Conditions
- Cervical Dystonia
- Interventions
- Other: No Intervention
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1046
- Registration Number
- NCT00836017
A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin
Completed
- Conditions
- Ocular Hypertension
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 50
- Registration Number
- NCT00834171
© Copyright 2025. All Rights Reserved by MedPath